Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

OPT

Phase 3

OPT-302

Wet AMD (Age-related macular degeneration)

Q2 2025

ShORe (w/Ranibizumab) and COAST (w/Aflibercept) studies: 3/3/25- Top-line COAST data in Q2 2025. Top-line ShORe data by mid-2025. BLA submission in H1 2026.

Data readout

IMRX

Phase 2a

IMM-1-104

Advanced Solid tumors (RAS Mutations), pancreatic cancer

Q2 2025

3/11/24- Dosed first patient. 7/31/24- Fast Track Designation in 1L & 2L PDAC. 3/20/25- Further data in Q2 2025.

Data readout

RXRX

Phase 2

REC-4881

AXIN1 or APC Mutant Cancers

H1 2025

LILAC trial. 11/6/24- Safety and preliminary efficacy data in H1 2025.

Data readout

AUPH

Phase 1

AUR200

Autoimmune diseases

Q2 2025

9/5/24- First participant dosed in SAD trial. 2/27/25- Initial results in Q2 2025.

Data readout

MLYS

Phase 2

Lorundrostat

Hypertensive patient w/ chronic kidney disease (CKD)

Q2 2025

Explore-CKD trial. 2/4/25- Enrollment complete. Topline data in Q2 2025.

Data readout

APGE

Phase 1b

APG808

Type 2 allergic reactions

H1 2025

3/25/24- Dosed first patient. 12/2/24- Reported interim Ph1 data. Now evaluating in a Ph1b trial in asthma, with data in H1 2025.

Data readout

KZR

Phase 2a

Zetomipzomib (KZR-616)

Autoimmune Hepatitis (AIH)

H1 2025

PORTOLA study. 8/13/24- Enrollment completed. 10/17/24 Positive IDMC review, continue without modification. 3/24/25- Present topline results on Mar 25th.

Data readout

YMAB

Phase 1

GD2-SADA

GD2-positive solid tumors [small cell lung cancer (SCLC), malignant melanoma, sarcomas and adult neuroblastoma]

Q2 2025

1001 study. 4/5/23- 1st patient dosed. 03/24- 1st cohort treated. 1/10/25- Part A data in Q2 2025. 1/31/25- Presented preclin & PK data at SNMMI & ACNM meetings.

Data readout

CRBU

Phase 1

CB-010

B-cell NHL (Non-Hodgkin Lymphoma)

H1 2025

ANTLER trial. 6/2/24- Presented initial DE data at ASCO '24. 3/10/25- Present data in H1 2025. Initiate Ph3 trial in H2 2025.

Data readout

ALT

Phase 2b

Pemvidutide (ALT-801) (GLP-1R/GCGR)

NASH (non-alcoholic steatohepatitis) & NAFLD (Non-alcoholic fatty liver disease)

Q2 2025

IMPACT trial. Present Ph1b 12wk NAFLD at NASH-TAG 2023 & 24wk at EASL 2023. 10/25/23- Presentation at The Liver Meeting '23. 10/26/23- Granted FDA fast-track designation. Enrollment commenced. 24-week trial data on Jan 6th, 2024 at NASH TAG.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20